Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Invested Capital (2019 - 2025)

Historic Invested Capital for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $538.7 million.

  • Nurix Therapeutics' Invested Capital rose 223.04% to $538.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $538.7 million, marking a year-over-year increase of 223.04%. This contributed to the annual value of $538.7 million for FY2025, which is 223.04% up from last year.
  • Per Nurix Therapeutics' latest filing, its Invested Capital stood at $538.7 million for Q4 2025, which was up 223.04% from $372.3 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Invested Capital ranged from a high of $538.7 million in Q4 2025 and a low of $168.7 million during Q1 2024
  • Its 5-year average for Invested Capital is $342.8 million, with a median of $342.4 million in 2021.
  • Per our database at Business Quant, Nurix Therapeutics' Invested Capital tumbled by 3842.48% in 2024 and then soared by 18499.12% in 2025.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Invested Capital stood at $342.3 million in 2021, then fell by 11.28% to $303.7 million in 2022, then crashed by 33.98% to $200.5 million in 2023, then soared by 162.85% to $527.0 million in 2024, then rose by 2.23% to $538.7 million in 2025.
  • Its Invested Capital was $538.7 million in Q4 2025, compared to $372.3 million in Q3 2025 and $447.6 million in Q2 2025.